Copyright 2024 All rights reserved.

Core Technology

We have developed and established all core technologies by ourselves

for the whole process from R&D to mass production of immune-tolerized EV therapeutics.

Core Technology

Overview

StemMedicare has been steadily conducting R&D to overcome various incurable diseases and congenital disorders through extracellular vesicles
without immune rejection and possesses core technologies for the entire process of development and manufacture of EV therapeutics.

Localization of materials / parts / equipment
Securing IPRs for core technologies

  • Cryopreservation

    Development of cryopreservatives
    replacing FBS and DMSO
    applicable in deep freezer
    Korea Registered
    Patent (2019)
    National New Excellent
    Technology (NET)
    Award (2020/2022)

  • Cultivation

    Development of
    FBS-free & ex-vivo cultivation
    system
    Korea Applied
    Patent (2014)

  • EV Production

    Development of

    mass production technology

    of extracellular vesicles
    Korea Registered
    Patent (2016)
    Japan Registered
    Patent (2019)
    US Registered
    Patent (2021)
    National New Excellent
    Technology (NET)
    Award (2013)

  • EV Isolation

    Development of

    mass isolation technology

    of extracellular vesicles without

    any damage
    Preparing domestic
    patent application

  • Induction of
    Immune tolerance

    Development of
    Cell lines and EVs
    without immune rejection
    for allogeneic use
    Korea Registered
    Patent (2019)
    Japan Registered
    Patent (2021)
    US Registered
    Patent (2023)
    Research Article
    Publishment (2020)

  • Development of
    EV therapeutics

    Development of
    EV therapeutics for atopy,
    anti-cancer, infections, OA,
    neurological diseases, etc
    Korea Registered
    Patent (2019)
    Japan Registered
    Patent (2023)
    US Registered
    Patent (2023)
    National New Excellent
    Technology (NET)
    Award (2021)
    Research Article
    Publishment (2022)